David de Graaf

Dr. de Graaf is a pioneer in the biotech industry with an impressive record of advancing programs into the clinic. Most recently, he was the CEO of Abcuro a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells.

Prior to that, David was CEO of Comet Therapeutics (acquired by VectivBio) and Syntimmune, a clinical-stage biotechnology company focused on advancing novel treatments for IgG-mediated autoimmune diseases which was acquired by Alexion.

His experience includes leadership roles at Apple Tree Partners, Selventa, Boehringer-Ingelheim, Pfizer and AstraZeneca. He holds a Ph.D. in genetics from the University of Illinois at Chicago.